The short version of AOD-9604 fits in a sentence. The long version — which is the one that helps — is below.
This page was last updated on 2025-11-02 and is reviewed periodically as new material appears.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to residues 176-191 of the 191-amino-acid hGH sequence. The fragment is not the full hormone and lacks the receptor-binding region associated with growth and metabolic effects of hGH. Researchers developed it to isolate a specific portion of hGH for study. Its exact sequence and length are often stated in peptide catalogs and patents.
The peptide is frequently described as a growth hormone fragment, although it is chemically distinct from full-length hGH. AOD-9604 contains 16 amino acids and includes two cysteine residues that can form an intramolecular disulfide bond. In solution, this structural feature can influence folding, aggregation, and stability. Published descriptions sometimes call it hGH 176-191 or AOD9604, with spacing and capitalization varying. Such naming differences can complicate literature searches, database entries, and product verification.
Researchers have studied the fragment in cell and animal models to understand its metabolic actions. Some experiments report effects on fat breakdown and fat storage pathways, but the underlying mechanism remains incompletely defined. AOD-9604 does not appear to stimulate the same broad growth hormone receptor signaling as full-length hGH. Whether its observed activities arise from direct receptor interactions or downstream metabolic changes is an open question. Results from different assays are not always consistent.
AOD-9604 is a synthetic peptide whose structure corresponds to a C-terminal segment of human growth hormone. It is often described as hGH fragment 176-191, a 16-amino-acid sequence. The peptide was designed to isolate a region of hGH associated with fat metabolism while avoiding the full hormone's growth-promoting actions. Laboratory and commercial materials typically present it as a lyophilized powder for research use. Its identity is defined by amino acid sequence, not by a single brand.
The fragment includes residues that can form an internal disulfide bond between two cysteine positions. This structural feature can influence how the peptide folds and how stable it is in solution. AOD-9604 differs from full-length hGH in size and receptor interactions; it does not contain the entire growth hormone sequence. Published descriptions sometimes use slightly different residue numbering, so sequence information should be checked against primary sources. The molecule is small compared with intact hGH, which affects analytical detection and purification approaches.
Interest in AOD-9604 arose from attempts to separate metabolic effects from growth effects attributed to hGH. Early work explored whether the fragment could influence lipolysis or fat oxidation without promoting growth. Those questions remain partly unresolved because human data are limited and results have varied across studies. The peptide is not a hormone replacement for hGH and is not equivalent to hGH in clinical use. Its research history includes both laboratory studies and commercial marketing claims that are not the same as regulatory approval.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Derived from a fragment of human growth hormone |
| Sequence basis | hGH residues 176-191 | Commonly described as a 16-amino-acid fragment |
| Appearance | White to off-white powder | Typical for lyophilized research peptides |
| Solubility | Soluble in water or aqueous buffer | Exact solubility depends on pH and purity |
| Common synonyms | AOD9604; hGH 176-191 | Spelling and punctuation vary across sources |
The compound has been studied as a potential treatment for obesity and related metabolic conditions. Published trials have examined changes in body weight, fat mass, and safety markers over limited durations. Results have been mixed or modest, and no large-scale outcome trials are established. Regulatory agencies in several countries have not approved it as a therapeutic drug. Some commercial products have been marketed outside regulated pharmaceutical channels, which raises questions about quality and claims.
In the scientific literature, AOD-9604 appears in reviews of growth hormone fragments and in discussions of peptide-based metabolic research. Some sources distinguish it from growth hormone itself, while others group it with compounds marketed for weight management. The evidence base is small compared with approved obesity medications. Questions about long-term efficacy and clinical relevance remain open, and independent replication of key findings is limited. Most published reports are early-stage and exploratory.
AOD-9604 is listed as a prohibited substance in sport by the World Anti-Doping Agency. It falls under the peptide hormones, growth factors, related substances, and mimetics class on the prohibited list. Anti-doping organizations treat its presence in an athlete's sample as an adverse finding unless a therapeutic use exemption applies. The prohibition reflects concerns about performance enhancement in competitive settings and the difficulty of distinguishing exogenous peptide use from endogenous hormone fragments.
Detection of AOD-9604 in biological samples relies on analytical techniques capable of distinguishing a small synthetic peptide from related endogenous sequences. Liquid chromatography coupled with tandem mass spectrometry is commonly used for confirmatory analysis. Sample preparation may involve immunoaffinity enrichment or solid-phase extraction to concentrate the peptide. Because the molecule is small and may be present at low concentrations, assay sensitivity and specificity are ongoing analytical challenges. Laboratories also validate methods against reference materials when available.
Regulatory interest in AOD-9604 increased after high-profile anti-doping cases involving peptide products. In some cases, the substance was supplied under alternative names or in compounded preparations, complicating traceability. Sports tribunals and anti-doping panels have discussed whether the peptide was explicitly banned at the time of use, leading to clarifications by the World Anti-Doping Agency. For consumers and researchers, the legal status can vary by jurisdiction, and products marketed as research chemicals may lack independent quality verification.
==== 1100–1199 ==== Welfare Food Amendment Regulations 1993 (S.I. 1993/1105) A630 Trunk Road (Rotherham) (Detrunking) Order 1993 (S.I. 1993/1107) Social Security (Claims and Payments) Amendment (No. 2) Regulations 1993 (S.I. 1993/1113) Local Fisheries Committees (Fees for Copy Byelaws) Order 1993 (S.I. 1993/1116) Legal Aid in Family Proceedings (Remuneration) (Amendment) Regulations 1993 (S.I. 1993/1117) Central and Fife Regions and Clackmannan and Dunfermline Districts (River Forth, Kilbagie Mill, Slack Cottage and River Black Devon) Boundaries Amendment Order 1993 (S.I. 1993/1118) Transport and Works Applications (Inland Waterways Procedure) Regulations 1993 (S.I. 1993/1119) Local Government Finance (Housing) (Consequential Amendments) (Amendment) Order 1993 (S.I. 1993/1120) Road Traffic (Training of Drivers of Vehicles Carrying Dangerous Goods) (Amendment) Regulations 1993 (S.I. 1993/1122) Value Added Tax (Education) (No. 2) Order 1993 (S.I. 1993/1124) Grampian Region (Electoral Arrangements) Order 1993 (S.I. 1993/1125) Moray Health Services National Health Service Trust (Appointment of Trustees) Order 1993 (S.I. 1993/1126) Royal Scottish National Hospital and Community National Health Service Trust (Appointment of Trustees) Order 1993 (S.I. 1993/1127) Royal Alexandra Hospital National Health Service Trust (Appointment of Trustees) Order 1993 (S.I. 1993/1128) Raigmore Hospital National Health Service Trust (Appointment of Trustees) Order 1993 (S.I. 1993/1129) Grampian Healthcare National Health Service Trust (Appointment of Trustees) Order 1993 (S.I.
In the developing world most snakebites occur in those who work outside such as farmers, hunters, and fishermen. They often happen when a person steps on the snake or approaches it too closely. In the United States and Europe, snakebites most commonly occur in those who keep them as pets. The type of snake that most often delivers serious bites depends on the region of the world. In Africa, it is mambas, Egyptian cobras, puff adders, and carpet vipers. In the Middle East, it is carpet vipers and elapids. In Latin America, it is snakes of the Bothrops and Crotalus types, the latter including rattlesnakes. In North America, rattlesnakes are the primary concern, and up to 95% of all snakebite-related deaths in the United States are attributed to the western and eastern diamondback rattlesnakes. The greatest number of bites are inflicted on the hands. People get bitten by handling snakes or in the outdoors by putting their hands on the wrong places. The next largest number of bites occur on the ankles, as snakes are often hidden or camouflaged extremely well to fend off predators. Most bite victims are bitten by surprise, and it is a comfortable fiction that rattlesnakes always forewarn their bite victims - often the bite is the first indication a snake is near.
Manuel Mendonça questioned the coincidences that the court used to come up with the hypothesis that unlinks Mendonça to Alcina Dias, given that, even if it was another child, it would not be normal for them to be accompanied by a man to meet with a prostitute, and that this event had not been investigated. In court, one of the inspectors of the first investigation team, José Ribeiro dos Santos, questioned the testimonies of Carlos Teixeira and Alcina Dias, even being interrupted multiple times so he would not tell testimonies of people that would later appear as witnesses. Ricardo Sá Fernandes said that the use of testimonies of the inspectors to discredit Alcina Dias in court, was illegal. According to lawyer Fernando Arrobas da Silva, the doubts raised in court were the reason a conviction was avoided in the 2012 trial.
Sources: en.wikipedia.org
== Nomenclature == This enzyme belongs to the family of oxidoreductases, specifically those acting on the CH-OH group of donor with NAD+ or NADP+ as acceptor. The systematic name of this enzyme class is 2-dehydro-3-deoxy-D-gluconate:NAD+ 5-oxidoreductase. Other names in common use include 2-keto-3-deoxygluconate 5-dehydrogenase, 2-keto-3-deoxy-D-gluconate dehydrogenase, 2-keto-3-deoxygluconate (nicotinamide adenine dinucleotide, (phosphate)) dehydrogenase, 2-keto-3-deoxy-D-gluconate (3-deoxy-D-glycero-2,5-hexodiulosonic, and acid) dehydrogenase.
There is a scientific consensus that currently available food derived from GM crops poses no greater risk to human health than conventional food, but that each GM food needs to be tested on a case-by-case basis before introduction. Nonetheless, members of the public are much less likely than scientists to perceive GM foods as safe. The legal and regulatory status of GM foods varies by country, with some nations banning or restricting them, and others permitting them with widely differing degrees of regulation. As late as the 1990s gene flow into wild populations was thought to be unlikely and rare, and if it were to occur, easily eradicated. It was thought that this would add no additional environmental costs or risks – no effects were expected other than those already caused by pesticide applications. However, in the decades since, several such examples have been observed. Gene flow between GM crops and compatible plants, along with increased use of broad-spectrum herbicides, can increase the risk of herbicide resistant weed populations. Debate over the extent and consequences of gene flow intensified in 2001 when a paper was published showing transgenes had been found in landrace maize in Mexico, the crop's center of diversity. Gene flow from GM crops to other organisms has been found to generally be lower than what would occur naturally. In order to address some of these concerns some GMOs have been developed with traits to help control their spread.
A protein called divalent metal transporter 1 (DMT1), which can transport several divalent metals across the plasma membrane, then transports iron across the enterocyte's cell membrane into the cell. If the iron is bound to heme it is instead transported across the apical membrane by heme carrier protein 1 (HCP1). These intestinal lining cells can then either store the iron as ferritin, which is accomplished by Fe2+ binding to apoferritin (in which case the iron will leave the body when the cell dies and is sloughed off into feces), or the cell can release it into the body via the only known iron exporter in mammals, ferroportin. Hephaestin, a ferroxidase that can oxidize Fe2+ to Fe3+ and is found mainly in the small intestine, helps ferroportin transfer iron across the basolateral end of the intestine cells. In contrast, ferroportin is post-translationally repressed by hepcidin, a 25-amino acid peptide hormone. The body regulates iron levels by regulating each of these steps. For instance, enterocytes synthesize more Dcytb, DMT1 and ferroportin in response to iron deficiency anemia. Iron absorption from diet is enhanced in the presence of vitamin C and diminished by excess calcium, zinc, or manganese. The human body's rate of iron absorption appears to respond to a variety of interdependent factors, including total iron stores, the extent to which the bone marrow is producing new red blood cells, the concentration of hemoglobin in the blood, and the oxygen content of the blood.
In most prokaryotes (archaea, bacteria), a single RNA polymerase species transcribes all types of RNA. RNA polymerase "core" from the bacteria E. coli consists of five subunits: two alpha (α) subunits of 36 kDa, a beta (β) subunit of 150 kDa, a beta prime subunit (β′) of 155 kDa, and a small omega (ω) subunit. A sigma (σ) factor binds to the core, forming the holoenzyme. After transcription starts, the σ factor can unbind and let the core enzyme perform transcription. The core RNA polymerase complex forms a "crab claw" or "clamp-jaw" structure with an internal channel running along the full length. Eukaryotic and archaeal RNA polymerases have a similar core structure and work in a similar manner, although they have many extra subunits. The 2006 Nobel Prize in Chemistry was awarded to Roger D. Kornberg for creating detailed molecular images of RNA polymerase during various stages of the transcription process. All RNAPs contain metal cofactors, in particular zinc and magnesium cations which aid in the transcription process.
Sources: en.wikipedia.org
When an action potential is triggered, the membrane potential abruptly shoots upward and then equally abruptly shoots back downward, often ending below the resting level, where it remains for some period of time. The shape of the action potential is stereotyped; this means that the rise and fall usually have approximately the same amplitude and time course for all action potentials in a given cell. (Exceptions are discussed later in the article) In most neurons, the entire process takes place in about a thousandth of a second. Many types of neurons emit action potentials constantly at rates of up to 10–100 per second. However, some types are much quieter, and may go for minutes or longer without emitting any action potentials.
== Public image == It is hard to gauge the opinion of the Chinese public on Xi, as no independent surveys exist in China and mentions of his name in social media are heavily censored. However, he is believed to be widely popular in the country. According to a 2014 poll co-sponsored by the Harvard Kennedy School's Ash Center for Democratic Governance and Innovation, Xi ranked 9 out of 10 in domestic approval ratings. A YouGov poll released in July 2019 found that about 22% of people in mainland China list Xi as the person they admire the most, a plurality, although this figure was less than 5% for residents of Hong Kong. In the spring of 2026, the Pew Research Center made a survey on confidence on Xi among 36 countries, which indicated that a median 34% have confidence in Xi to do the right thing regarding world affairs, meanwhile a median of 53% have no confidence; these numbers are higher than those of Russian President Vladimir Putin (31% confidence, 65% no confidence) and United States President Donald Trump (23% confidence, 76% no confidence). In 2017, The Economist named him the most powerful person in the world. In 2018, Forbes ranked him as the most powerful and influential person in the world, replacing Russian President Vladimir Putin, who had been ranked so for five consecutive years. In 2022, Time also named Xi as the world's most powerful person, writing Xi "is the first among 1.4 billion people.
In the 1990s, the German Federal Intelligence Service (BND) obtained a sample of one Novichok agent from a Russian scientist, and the sample was analysed in Sweden, according to a 2018 Reuters report. The chemical formula was given to Western NATO countries, who synthesized it, then used small amounts to test protective equipment, detection of it, and antidotes to it. Novichok was referred to in a patent filed in 2008 for an organophosphorus poisoning treatment. The University of Maryland, Baltimore research was funded in part by the U.S. Army. Professor Leonid Rink, who said he had participated in the creation of Novichok agents, confirmed that the structures leaked by Mirzayanov were the correct ones. Rink was himself convicted in Russia for illegally selling a Novichok agent used in 1995 to assassinate a banker, Ivan Kivelidi, and his secretary. David Wise, in his book Cassidy's Run, implies that the Soviet program may have been the unintended result of misleading information, involving a discontinued American program to develop a nerve agent code named "GJ", that was fed by a double agent to the Soviets as part of Operation Shocker.
Sources: en.wikipedia.org
No, it is a synthetic peptide fragment corresponding to a small portion of hGH. It is not the full 191-amino-acid hormone and does not reproduce all of hGH's effects.
It is commonly described as a 16-amino-acid peptide based on residues 176-191 of human growth hormone. Some sources vary in notation, so checking the stated sequence is useful.
It is not typically described as a standalone natural hormone. The sequence is derived from the C-terminal region of human growth hormone, but the synthetic peptide is a laboratory-made construct.
It is a synthetic peptide based on a C-terminal fragment of human growth hormone. It is commonly referred to as hGH fragment 176-191 and is studied for metabolic effects rather than growth effects.